Gilead Sciences (GILD) Invested Capital (2009 - 2026)

Gilead Sciences has reported Invested Capital for 18 years, with the latest figure at $45.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 3.77% year-over-year to $45.7 billion; the trailing twelve-month figure through Mar 2026 stood at $45.7 billion (up 3.77% YoY), and the FY2025 full-year result was $47.6 billion, up 3.66% from the prior year.
• Invested Capital for Q1 2026 stood at $45.7 billion, down from $47.6 billion in the prior quarter.
• The five-year high for Invested Capital was $47.7 billion in Q4 2023, with the low at $41.5 billion in Q2 2024.
• Historically, Invested Capital has averaged $45.5 billion across 5 years, with a median of $46.2 billion in 2023.
• Annual changes were most pronounced in 2024 — Invested Capital decreased 11.83% — and 2025, when it grew 11.63%.
• Gilead Sciences' Invested Capital stood at $46.4 billion in 2022, then rose by 2.8% to $47.7 billion in 2023, then declined by 3.73% to $46.0 billion in 2024, then rose by 3.66% to $47.6 billion in 2025, then slipped by 4.1% to $45.7 billion in 2026.
• The last three Invested Capital figures came in at $45.7 billion (Q1 2026), $47.6 billion (Q4 2025), and $46.5 billion (Q3 2025), per Business Quant data.